Success Metrics

Clinical Success Rate

66.7%

Based on 2 completed trials

Completion Rate

67%(2/3)

Active Trials

1(20%)

Results Posted

100%(2 trials)

Terminated

1(20%)

Phase Distribution

Ph phase_2

40%

Ph early_phase_1

20%

Ph phase_1

20%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Early Phase 1First-in-human

1(25.0%)

Phase 1Safety & dosage

1(25.0%)

Phase 2Efficacy & side effects

2(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(2)

Terminated(1)

Other(1)

Detailed Status

Completed2

unknown1

Terminated1

Recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

66.7%

Most Advanced

Phase 2

Trials by Phase

Early Phase 11 (25.0%)

Phase 11 (25.0%)

Phase 22 (50.0%)

Trials by Status

completed240%

unknown120%

terminated120%

recruiting120%

Recent Activity

1 active trials

Showing 5 of 5

completedearly_phase_1

Bethanechol Prior to Pancreatic Surgery

NCT03572283

recruitingphase_2

Stimulation With Bethanechol in Combination With Gemcitabine and Nab-paclitaxel in Pancreatic Adenocarcinoma

NCT05241249

unknown

Clinical Trials (5)

Showing 5 of 5 trials

NCT03572283Early Phase 1

Bethanechol Prior to Pancreatic Surgery

Completed

NCT05241249Phase 2

Stimulation With Bethanechol in Combination With Gemcitabine and Nab-paclitaxel in Pancreatic Adenocarcinoma

Recruiting

NCT05299008

The Effect of Bethanechol on Tracheobronchomalacia

Unknown

NCT02058537Phase 2

Bethanechol for Eosinophilic Esophagitis

Terminated

NCT01031043Phase 1

Topical Bethanechol for Improvement of Esophageal Dysmotility

Completed

All 5 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 5